Investing and Economic Commentary

Earlier this week, we established a new position in Starbucks Corporation (SBUX) as we seek to take advantage of the market downturn, using the current environment to add high-quality companies to portfolios without compromising on price.
You may have noticed an unusually large number of trade confirmations from Schwab lately and be wondering what trades are being made in your accounts and why.
With stocks sharply selling-off over the last several weeks, we are looking for opportunities to add exposure to high-quality names at discounted prices. Consistent with this strategy, we have recently added Microsoft Corporation (MSFT) to portfolios.
The coronavirus situation continues to escalate and change on virtually a daily basis. The past week has disrupted life for most of us in a number of important ways.
The coronavirus, and the fear of its potential impact on the global economy, has roiled the financial markets. Domestic stock indices were down double digits last week, followed by a massive rebound yesterday.
Earlier this week, we made several transactions on behalf of our clients. While transactions varied by account, they consisted primarily of a portfolio rebalancing and replacing the Invesco S&P International Developed Low Volatility ETF (IDLV) with the Schwab International Equity ETF (SCHF).
We recently added Booking Holdings (BKNG) to portfolios in our individual stock strategy. As a matter of quick background,
Your team at Kays Financial recently reduced positions in the Invesco S&P SmallCap Low Volatility ETF (XSLV) and added emerging market exposure through the Vanguard Emerging Markets Select Stock Fund (VMMSX).
We recently added Huntsman Corporation (HUN) to portfolios at what we believe to be a bargain price at just ~7.0x next twelve months expected earnings. As a matter of background, Huntsman is a global manufacturer of chemical products.
Last week, we added Allergan (AGN) to portfolios, which we view as an inexpensive stock offering an attractive risk/reward profile for patient investors. As a matter of quick background, Allergan is a global pharmaceutical company that focuses on four therapeutic areas, including medical aesthetics, eye care, the central nervous system, and gastroenterology.

Pages